Sterling Drug is an authorized DME supplier for medicare equipments and products.
Sterling Drug is a Community/Retail Pharmacy in Austin, Minnesota. This pharmacy is owned and operated by Astrup Drug Inc. It is located at 1305 1st Ave Sw, Austin and it's customer support contact number is 507-433-4586. The authorized person of Sterling Drug is David Brooks who is District Pharmacy Manager of the pharmacy and his contact number is 612-618-6340. Active license number of Sterling Drug is 264435 for Community/Retail Pharmacy in Minnesota. Sterling Drug accepts medicare which means medicare covered patients will not be billed for any more than the Medicare deductible and coinsurance. Sterling Drug is a pharmacy where pharmacists store, prepare, and dispense medicinal preparations and/or prescriptions for a local patient population in accordance with federal and state law; counsel patients and caregivers (sometimes independent of the dispensing process); administer vaccinations; and provide other professional services associated with pharmaceutical care such as health screenings, consultative services with other health care providers, collaborative practice, disease state management, and education classes.
Pharmacy Details:
Sterling Drug type, location, contact phone number and fax are as below. Patients can directly walkin to the pharmacy or can call on the below given customer support phone number for enquiries.
Name:
Sterling Drug
Type:
Community/Retail Pharmacy
Location:
1305 1st Ave Sw, Austin, Minnesota, 55912-1601
Phone:
507-433-4586
Fax:
507-433-7003
Authorized/Official Person Profile:
Officially authorized person to contact for any management issues or complaints of this pharmacy is as below. Person's position and contact details are also mentioned below.
Name:
David Brooks
Position:
District Pharmacy Manager
Contact Number:
612-618-6340
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of given pharmacy are as mentioned below.
NPI Number:
1811932346
NPI Enumeration Date:
18 Jun, 2006
NPI Last Update On:
22 Mar, 2017
Medical Licenses:
Organizations can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Sterling Drug are as mentioned below.
Specialization
License Number
State
Status
Community/Retail Pharmacy
264435
Minnesota
Primary
Pharmacy
Secondary
Other Medical Identifiers:
Other legacy medical identifiers of the pharmacy such as Medicaid, Medicare PIN, NSC, UPIN etc. are mentioned as below.
Identifier
Type
State
Issuer
498358100
Medicaid
Minnesota
2043955
Other
Pk
Medicare Enrollment:
Sterling Drug is enrolled in medicare and it's Pac Id, enrollment Id, registered name and type is as stated below.
PAC ID:
Enrollment ID:
Org Name
Medicare Entity Type
7810993623
O20061018000102
Astrup Drug Inc
PART B SUPPLIER - MASS IMMUNIZATION (ROSTER BILLER ONLY)
7810993623
O20100930026915
Astrup Drug Inc
DME SUPPLIER - PHARMACY
Products Available:
Sterling Drug has following products available for sale under medicare.
Products
Blood Glucose Monitors & Supplies: Non-mail Order
Canes & Crutches
Commodes, Urinals, & Bedpans
Diabetic Shoes & Inserts: Prefabricated
Enteral Nutrients
Heat & Cold Applications
Nebulizer Equipment & Supplies
Orthoses: Off-the-shelf
Ostomy Supplies
Seat Lift Mechanisms
Surgical Dressings
Urological Supplies
Walkers
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
905 N Main St, Po 658 Austin, Minnesota
Zip:
55912-3357
Phone Number:
507-433-7447
Fax Number:
507-433-1632
Patients can reach Sterling Drug at 1305 1st Ave Sw, Austin, Minnesota or can call on customer care at 507-433-4586.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.